XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Business Acquisition - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 14, 2020
Sep. 30, 2020
Dec. 31, 2019
Business Acquisition [Line Items]      
Common stock, par value   $ 0.001 $ 0.001
Business acquisition costs   $ 2,200  
Goodwill   44,466  
General and Administrative [Member]      
Business Acquisition [Line Items]      
Business acquisition costs   $ 2,200  
Anelixis [Member]      
Business Acquisition [Line Items]      
Business acquisition, date of acquisition Sep. 14, 2020    
Common stock, par value $ 0.001    
Estimated fair value related to clinical development program $ 32,386    
Goodwill 44,466    
Anelixis [Member] | In-Process Research and Development [Member]      
Business Acquisition [Line Items]      
Estimated fair value related to clinical development program $ 32,400    
Anelixis [Member] | Series X1 Preferred Stock [Member]      
Business Acquisition [Line Items]      
Shares Issued to stockholders of acquiree 140,026    
Anelixis [Member] | Series X1 Preferred Stock [Member] | Stock Purchase Agreement [Member]      
Business Acquisition [Line Items]      
Preferred stock shares agreed to sell 199,112    
Preferred stock shares aggregate purchase price $ 99,100    
Business combination additional commitments in equity financing $ 9,000    
Anelixis [Member] | Common Stock [Member]      
Business Acquisition [Line Items]      
Shares Issued to stockholders of acquiree 175,488    
Shares of common stock issued upon conversion of each share of preferred stock 55.5556    
Anelixis [Member] | Common Stock [Member] | Series X1 Preferred Stock [Member] | Stock Purchase Agreement [Member]      
Business Acquisition [Line Items]      
Shares of common stock issued upon conversion of each share of preferred stock 55.5556